Sustainable Practices in Medicinal Chemistry: Current State and Future Directions

被引：172

作者：

Bryan, Marian C. ^{[1
]}

Dillon, Barry ^{[2
]}

Hamann, Lawrence G. ^{[3
]}

Hughes, Gregory J. ^{[4
]}

Kopach, Michael E. ^{[5
]}

Peterson, Emily A. ^{[6
]}

Pourashraf, Mehrnaz ^{[7
]}

Raheem, Izzat ^{[8
]}

Richardson, Paul ^{[9
]}

Richter, Daniel

Sneddon, Helen F. ^{[10
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] AstraZeneca, Brixham Environm Lab, Brixham TQ5 8BA, Devon, England

[3] Novartis Inst BioMed Res, Cambridge, MA 02139 USA

[4] Merck, Rahway, NJ 07065 USA

[5] Eli Lilly & Co, Indianapolis, IN 46285 USA

[6] Amgen Inc, Cambridge, MA 02142 USA

[7] AstraZeneca, R&D Montreal, St Laurent, PQ H4S 1Z9, Canada

[8] Merck, West Point, PA 19486 USA

[9] Pfizer Global Res & Dev, San Diego, CA 92121 USA

[10] GlaxoSmithKline, Med Res Ctr, Stevenage SG1 2NY, Herts, England

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2013年 / 56卷 / 15期

关键词：

GREEN CHEMISTRY; PHARMACEUTICAL-INDUSTRY; ENZYMATIC REDUCTION; ORGANIC-SYNTHESIS; ROOM-TEMPERATURE; CROSS-COUPLINGS; DRUG DISCOVERY; SOLVENT; REPLACEMENT; PERSPECTIVE;

D O I：

10.1021/jm400250p

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The medicinal chemistry subgroup of the American Chemical Society's Green Chemistry Institute Pharmaceutical Roundtable (ACS GCI PR) offers a perspective on the current state of environmentally sustainable practices in medicinal chemistry with the aim of sharing best practices more widely and highlighting some potential future developments.

引用

页码：6007 / 6021

页数：15

共 61 条

[1] Green chemistry tools to influence a medicinal chemistry and research chemistry based organisation
Alfonsi, Kim
Colberg, Juan
Dunn, Peter J.
Fevig, Thomas
Jennings, Sandra
Johnson, Timothy A.
Kleine, H. Peter
Knight, Craig
Nagy, Mark A.
Perry, David A.
Stefaniak, Mark
[J]. GREEN CHEMISTRY, 2008, 10 (01) : 31 - 36
[2] Anastas P.T., 1998, Green chemistry: theory and practice
[3] [Anonymous], 2012, ACCOUNTS CHEM RES
[4] Key green chemistry research areas - a perspective from pharmaceutical manufacturers
Constable, David J. C.
Dunn, Peter J.
Hayler, John D.
Humphrey, Guy R.
Leazer, Johnnie L., Jr.
Linderman, Russell J.
Lorenz, Kurt
Manley, Julie
Pearlman, Bruce A.
Wells, Andrew
Zaks, Aleksey
Zhang, Tony Y.
[J]. GREEN CHEMISTRY, 2007, 9 (05) : 411 - 420
[5] Perspective on solvent use in the pharmaceutical industry
Constable, David J. C.
Jimenez-Gonzalez, Conchita
Henderson, Richard K.
[J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2007, 11 (01) : 133 - 137
[6] Cooper G. S., 2011, TOXICOLOGICAL REV DI
[7] Divergent C-H Functionalizations Directed by Sulfonamide Pharmacophores: Late-Stage Diversification as a Tool for Drug Discovery
Dai, Hui-Xiong
Stepan, Antonia F.
Plummer, Mark S.
Zhang, Yang-Hui
Yu, Jin-Quan
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2011, 133 (18) : 7222 - 7228
[8] Catalytic C-H functionalization by metal carbenoid and nitrenoid insertion
Davies, Huw M. L.
Manning, James R.
[J]. NATURE, 2008, 451 (7177) : 417 - 424
[9] Eames J, 2001, EUR J ORG CHEM, V2001, P1213
[10] Optimisation of solvent replacement procedures according to economic and environmental criteria
Elgue, S
Prat, L
Cabassud, M
Cézerac, J
[J]. CHEMICAL ENGINEERING JOURNAL, 2006, 117 (02) : 169 - 177

← 1 2 3 4 5 6 7 →